Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
The final month of 2018 will see FDA verdicts on Roche’s bid to play in the first-line lung cancer space, and what Jazz hopes will be its next big narcolepsy product.
Pain drugs look like they could face different outcomes, while targeted cancer agents will have a big month. Two biosimilar decisions also await.
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.